PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer.
Publication/Presentation Date
3-23-2023
Abstract
UNLABELLED: Prostate cancer (PCa) is the second leading cause of cancer death for men in the United States. While organ-confined disease has reasonable expectation of cure, metastatic PCa is universally fatal upon recurrence during hormone therapy, a stage termed castration-resistant prostate cancer (CRPC). Until such time as molecularly defined subtypes can be identified and targeted using precision medicine, it is necessary to investigate new therapies that may apply to the CRPC population as a whole. The administration of ascorbate, more commonly known as ascorbic acid or Vitamin C, has proved lethal to and highly selective for a variety of cancer cell types. There are several mechanisms currently under investigation to explain how ascorbate exerts anti-cancer effects. A simplified model depicts ascorbate as a pro-drug for reactive oxygen species (ROS), which accumulate intracellularly and generate DNA damage. It was therefore hypothesized that poly(ADP-ribose) polymerase (PARP) inhibitors, by inhibiting DNA damage repair, would augment the toxicity of ascorbate.
RESULTS: Two distinct CRPC models were found to be sensitive to physiologically relevant doses of ascorbate. Moreover, additional studies indicate that ascorbate inhibits CRPC growth
CONCLUSIONS: These data indicate that pharmacological ascorbate is an effective monotherapy at physiological concentrations and kills CRPC cells. Ascorbate-induced tumor cell death was associated with disruption of cellular energy dynamics and accumulation of DNA damage. The addition of PARP inhibition increased the extent of DNA damage and proved effective at slowing CRPC growth both
ISSN
2692-8205
Published In/Presented At
Gordon, N., Gallagher, P. T., Neupane, N. P., Mandigo, A. C., McCann, J. K., Dylgjeri, E., Vasilevskaya, I., McNair, C., Paller, C. J., Kelly, W. K., Knudsen, K. E., Shafi, A. A., & Schiewer, M. J. (2023). PARP inhibition and pharmacological ascorbate demonstrate synergy in castration-resistant prostate cancer. bioRxiv : the preprint server for biology, 2023.03.23.533944. https://doi.org/10.1101/2023.03.23.533944
Disciplines
Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods
PubMedID
36993449
Department(s)
Administration and Leadership
Document Type
Article